ev3 Inc. Archives - Page 2 of 4

Medtronic shareholder sues over company’s plan to cover nearly $58M in taxes | Medtech legal news for the week of October 13, 2014

October 13, 2014 By MassDevice Leave a Comment

Shareholder sues Medtronic over plan to cover execs' $58m tax tab

October 7, 2014 by Brad Perriello

Covidien’s Ev3 logs a pair of legal wins over Appriva, whistleblower

October 8, 2014 By Brad Perriello Leave a Comment

Medtech legal news for the week of Mar. 17, 2014

March 17, 2014 By MassDevice staff Leave a Comment

Appeals court applies Supreme Court ruling to Medtronic lawsuit against Boston Scientific

March 12, 2014 by Brad Perriello

Covidien’s ev3 seeks new trial in $175M loss to Appriva

March 13, 2014 By Brad Perriello Leave a Comment

Covidien (NYSE:COV) subsidiary ev3 wants the Delaware Supreme Court to grant a new trial in a lawsuit over $175 million ev3 allegedly owes its own Appriva Medical acquisition.

Covidien’s got a ‘new approach’ to peripheral arterial disease

October 15, 2013 By Arezu Sarvestani Leave a Comment

Jury hands Covidien’s ev3 subsidiary a possible $275M loss

August 13, 2013 By Brad Perriello Leave a Comment

Jury hands Covidien's ev3 subsidiary a possible $265M loss

Covidien (NYSE:COV) is on the hook for a $175 million milestone owed by subsidiary ev3 Inc. to a company it acquired 11 years ago, plus another possible $100 million in interest, after a Delaware jury’s decision last May.

Aneurysm: Covidien touts pivotal study on Pipeline embolization device

June 17, 2013 By Brian Johnson Leave a Comment

Covidien (NYSE:COV) subsidiary ev3 Inc. is touting the results of a pivotal trial of its Pipeline aneurysm embolization device, showing that the technology "offers a reasonably safe and effective treatment of large or giant intracranial internal carotid artery aneurysms."

Mixed feelings for Covidien’s Pipeline embolization device following deaths

December 6, 2012 By MassDevice staff Leave a Comment

Researchers offered mixed messages on the safety and effectiveness of Covidien (NYSE:COV) subsidiary ev3 Inc.’s Pipeline embolization device, lauding the system as an option for patients with aneurysms that may not otherwise be treatable but warning of a significant risk of serious complications.

Layoffs: Covidien to shutter South Carolina plant, cutting 595 jobs

September 13, 2012 By MassDevice staff Leave a Comment

Covidien (NYSE:COV) will close a manufacturing facility in Seneca, S.C., and move the operation to Costa Rica, resulting in nearly 600 layoffs.

The Seneca facility manufactures vascular products for the Mansfield, Mass.-based medical device company.

FDA warns on Covidien’s liquid embolic system following 9 patient deaths

July 10, 2012 By MassDevice staff Leave a Comment

The FDA issued a safety alert after receiving reports of more than 100 adverse events, including 9 patient deaths, that may have been caused by Onyx brain blood vessel plugs made by Covidien (NYSE:COV) subsidiary ev3 Inc.

Covidien touts FDA clearance for “game-changing” Solitaire revascularization device

March 5, 2012 By MassDevice staff Leave a Comment

Covidien plc (NYSE:COV) won FDA clearance for its Solitaire FR revascularization device for removing blood clots and restoring blood flow in the brains of patients suffering acute ischemic stroke.

The federal watchdog agency cleared the device, which physically removes blood clots from vessels, on the basis of data gathered during Covidien’s Swift study, the first of its kind to compare mechanical interventions for acute ischemic stroke, according to a press release.